FOR IMMEDIATE RELEASE
MEDIA CONTACTS:
AUA Media Relations: 410-689-3932
Wendy Waldsachs Isett (cell): 410-977-4770
AUA ANNOUNCES 2011 ANNUAL AWARD WINNERS
Awards Recognize Top Urologists, Honor Service to Specialty and Society
LINTHICUM, MD, January 18, 2011–The American Urological Association today announced the list of
2011 award recipients who will be honored at the Association’s upcoming Annual Meeting in
Washington, DC, this May. These physician researchers and educators are being honored for their
contributions to the field of medicine, the specialty of urology, and the AUA.
The following awards will be presented:
Ramon Guiteras Award: The Ramon Guiteras Award is presented annually to an individual who is
deemed to have made outstanding contributions to the art and science of urology. E. Darracott
Vaughan Jr., MD, will receive this award for outstanding contributions to the science of urology, most
notably in the pathophysiology of renal obstruction, adrenal disease and benign prostatic hyperplasia
(BPH).
Hugh Hampton Young Award: The Hugh Hampton Young Award is presented annually to an individual
for outstanding contributions to the study of genitourinary tract disease. William D. Steers, MD, will
receive this award for his outstanding contributions in urological education and pharmacology of the
genitourinary tract, including female urology, urinary incontinence and neurogenic bladder.
Gold Cystoscope Award: The Gold Cystoscope Award is presented annually to a urologist distinguished
by outstanding contributions to the profession within 13 years of completing residency training. Sam S.
Chang, MD, will receive this award for outstanding contributions in the field of bladder and prostate
cancer, as well as the integration of evidence-based urological oncology into clinical pathways, practice
guidelines and the AUA Core Curriculum.
Lifetime Achievement Award: The Lifetime Achievement Award is presented annually to an individual
who has been deemed to have made outstanding contributions to advance the mission and goals of the
AUA. Arthur D. Smith, MD, will receive this award for lifetime dedication to the development of the
field of endourology.
Victor A. Politano Award: The Victor A. Politano Award is presented annually to an individual for
outstanding research and work in the field of incontinence and for enhancing the treatment of
incontinent patients, thereby helping to improve their quality of life. George D. Webster, MD, will
receive this award in recognition of outstanding contributions in incontinence, female urology and
reconstructive surgery.
William P. Didusch Art and History Award: The William P. Didusch Art and History Award promotes and
recognizes contributions to urological art, including, but not limited to, illustrations, sculpture, still
photography, motion pictures and television productions. Robert Meyer, MD, will receive this award for
his outstanding photographic documentation and written contributions to urologic history in the United
States and Canada.
Distinguished Contribution Award: The Distinguished Contribution Awards are presented annually to
individuals who have made outstanding contributions to the science and practice of urology, including,
but not limited to, contributions made in a sub-specialty area, for military career service or for
humanitarian efforts. Three AUA members will receive this award:
 Culley C. Carson III, MD, for outstanding contributions to the understanding and management
of the urological aspects of sexual medicine
 Michael A. S. Jewett, MD, for outstanding contributions to the science and treatment of
urological malignancies
 Anthony W. Middleton Jr., MD, for outstanding contributions in health policy, socioeconomics,
managed care and survey analysis on the national, Section and state levels
Distinguished Service Awards: The Distinguished Service Awards are presented annually to individuals
who are deemed to have made outstanding contributions to the goals of the AUA. The following
individuals will receive this award:
 Richard K. Babayan, MD, for outstanding service to the AUA Foundation, AUA Leadership
Program and the AUA Board of Directors
 Harris M. Nagler, MD, for outstanding contributions to the goals of the AUA through service as
the chair of the Judicial & Ethics Committee
 Mark S. Litwin, MD, MPH, for outstanding contributions to the goals of the AUA through
committee service and editorial contributions to urological publications, including the Urologic
Diseases in America Project
Gold Cane Award: The Gold Cane Award is presented to a senior urologist distinguished by outstanding
contributions to the profession and to the AUA. David T. Uehling, MD, will receive this award for his
outstanding contributions in investigations of urinary tract infections and clinical expertise in pediatric
urology.
Presidential Citations: Presidential Citations are presented to individuals deemed to have significantly
promoted the cause of urology during a specific period of time. Each recipient is chosen by the AUA
President. Six Presidential Citations will be presented to honor the following individuals:
 Jack L. Sales, MD, for a lifetime of exemplary service to the American and Canadian Urological
Associations and for establishing the CUA and Northeastern Section Foundations
 Ajit Gangadhar Phadke, MD, for outstanding contributions in establishing and fostering
progressive international relations with the AUA
 Jorge Elias Dib, MD, for his dedication to urology in Mexico and fostering collaborations with
the AUA through the South Central Section
 Frank J. DeSantis, CAE, for more than 45 years of outstanding administrative management of
the AUA Western Section


Shlomo Raz, MD, for outstanding contributions in the field of female reconstructive surgery and
strengthening urologic education in Mexico and South America
Michael T. Sheppard, CPA, CAE for dedicated service as the Executive Director, advancing the
AUA through new opportunities and leadership in navigating the complexities and challenges of
association management
“These awards are testimony to the work of individuals who have made significant contributions to our
subspecialty,” said AUA Awards Committee Chair Paul F. Schellhammer, MD. “We will be honored to
recognize the recipients at our annual meeting in Washington DC.”
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the
American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000
members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the
highest standards of urologic care by carrying out a wide variety of programs for members and their patients.
###
#1481
UTILIZATION OF NEPHRON-SPARING SURGERY AMONG RENAL CELL CARCINOMA PATIENTS WITH
DIABETES OR HYPERTENSION
Christopher Filson*, David Miller, Ann Arbor, MI, Julie Ruterbusch, Detroit, MI, Joanne Colt, Wong-Ho
Chow, Bethesda, MD, Kendra Schwartz, Detroit, MI
Introduction and Objectives: Nephron-sparing surgery (NSS) is the preferred treatment for patients with
early-stage kidney cancer and concurrent risk factors for chronic kidney disease (CKD). In this context,
we used population-based data from National Cancer Institute’s U.S. Kidney Cancer Study (KCS) to
evaluate whether receipt of NSS is more common among patients with renal cell carcinoma (RCC) and
concurrent diabetes mellitus (DM) or hypertension (HTN).
Methods: The KCS is a population-based case–control study conducted in the metropolitan areas of
Detroit and Chicago from 2002-2007. During the study interval, 1,136 patients with kidney cancer
consented to both an epidemiological interview and medical record review. From these sources, we
ascertained detailed information regarding patient demographics, medical comorbidities, clinical and
pathological characteristics of the kidney cancer, and treatment(s) received. We then used bivariate
statistical analyses to evaluate differences in the frequency of NSS among patients with or without DM
or HTN, including analyses stratified by tumor size.
Results: Our analytic cohort comprised 894 cases treated surgically for RCC. Among this group, 183
patients (20.5%) underwent NSS; this proportion increased to 34.3% among cases with tumors ≤ 4 cm
(p<0.01). Overall, 17% and 59% of patients in the analytic cohort had DM or HTN, respectively.
Compared to patients with neither DM nor HTN, the use of NSS was similar for patients with DM alone
(19% vs 16% if DM alone, p=0.65) or HTN alone (19% vs 20% if HTN alone, p=0.71); this finding was
consistent among patients with tumors ≤ 4cm. However, patients with both HTN and DM were
significantly more likely to receive NSS, compared to patients who did not have either diagnosis (28% vs
19%, p=0.04, Figure).
Conclusions: NSS is performed in up to one-third of patients with early-stage kidney cancer, and more
frequently among RCC patients with both DM and HTN. However, the finding that NSS is not applied
with relatively greater frequency among patients with small renal tumors and important individual CKD
risk factors (DM or HTN alone) suggests an immediately-available opportunity to improve surgical care
for patients with RCC.
Source of Funding: National Institutes of Health Intramural Research Program; The New York Academy
of Medicine